WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$4.74 USD
-0.27 (-5.39%)
Updated Apr 25, 2024 03:59 PM ET
After-Market: $4.76 +0.02 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for WAVE Life Sciences Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 200 | 89 | 151 | 185 | 147 |
Receivables | 21 | 0 | 0 | 30 | 20 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 14 | 10 | 12 | 16 | 18 |
Total Current Assets | 235 | 99 | 163 | 230 | 185 |
Net Property & Equipment | 13 | 17 | 22 | 29 | 36 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 30 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 4 | 4 | 4 | 14 |
Total Assets | 275 | 146 | 207 | 279 | 284 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 13 | 17 | 7 | 14 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 17 | 18 | 15 | 12 | 16 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 150 | 32 | 37 | 92 | 90 |
Total Current Liabilities | 186 | 72 | 64 | 121 | 118 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 16 | 80 | 77 | 41 | 63 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 2 |
Minority Interest (Liabilities) | 8 | 8 | 8 | 8 | 8 |
Total Liabilities | 235 | 191 | 175 | 196 | 221 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 935 | 803 | 750 | 694 | 540 |
Capital Surplus | 129 | 119 | 88 | 72 | 57 |
Retained Earnings | -1,025 | -967 | -806 | -683 | -533 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 40 | -45 | 33 | 83 | 64 |
Total Liabilities & Shareholder's Equity | 275 | 146 | 207 | 279 | 284 |
Total Common Equity | 40 | -45 | 33 | 83 | 64 |
Shares Outstanding | 99.00 | 86.90 | 58.80 | 48.70 | 34.20 |
Book Value Per Share | 0.40 | -0.52 | 0.55 | 1.70 | 1.86 |
Fiscal Year End for WAVE Life Sciences Ltd falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 200 | 140 | 173 | 208 |
Receivables | NA | 21 | 7 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 14 | 12 | 12 | 12 |
Total Current Assets | NA | 235 | 159 | 185 | 220 |
Net Property & Equipment | NA | 13 | 14 | 15 | 16 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 4 | 4 | 5 | 6 |
Total Assets | NA | 275 | 200 | 230 | 267 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 13 | 13 | 12 | 12 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 17 | 13 | 10 | 8 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 150 | 68 | 111 | 107 |
Total Current Liabilities | NA | 186 | 100 | 140 | 133 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 16 | 105 | 105 | 131 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 8 | 8 | 8 | 8 |
Total Liabilities | NA | 235 | 240 | 282 | 302 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 935 | 841 | 840 | 838 |
Capital Surplus | NA | 129 | 127 | 125 | 122 |
Retained Earnings | NA | -1,025 | -1,009 | -1,016 | -995 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 40 | -40 | -52 | -35 |
Total Liabilities & Shareholder's Equity | NA | 275 | 200 | 230 | 267 |
Total Common Equity | 0 | 40 | -40 | -52 | -35 |
Shares Outstanding | 122.20 | 99.00 | 98.90 | 98.90 | 98.30 |
Book Value Per Share | 0.00 | 0.40 | -0.41 | -0.52 | -0.35 |